Coronavirus Vaccine: Oxford’s vaccine will be ready by christmas, says lead researcher   | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
July 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JULY 14, 2025
Oxford’s vaccine will be ready by christmas, says lead researcher  

Coronavirus chronicle

TBS Report
26 October, 2020, 03:15 pm
Last modified: 26 October, 2020, 03:59 pm

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Somber Christmas in Bethlehem in the shadow of Gaza war

Oxford’s vaccine will be ready by christmas, says lead researcher  

Phase three trials are now at an advanced stage

TBS Report
26 October, 2020, 03:15 pm
Last modified: 26 October, 2020, 03:59 pm
Sample from patients are analysed as part of the trial. Photo: BBC.
Sample from patients are analysed as part of the trial. Photo: BBC.

Medics and high-risk patients are likely to receive Oxford's Covid-19 vaccine before the end of the year, according to the professor leading the vaccine project of Oxford University.  

Professor Adrian Hill founder and director of the Jenner Institute of the University of Oxford's indicated that emergency approval would allow those most in need to receive the jab while the final trials are still under way, reports The Daily Mail. 

Full authorisation would then follow, meaning the rest of the population could receive the vaccine from early 2021.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

He admitted timing was tight to begin vaccinations before Christmas – but insisted it was indeed possible.

In an upbeat assessment of how the vaccination programme could unfold, he said, "'I'd be very surprised if this thing [the pandemic] isn't very clearly on the way down by late spring, at least in this country... we will get to the stage where there is herd immunity through vaccination."

Two phases of successful clinical trials have established the Oxford vaccine is safe and triggers a strong immune response.

Phase three trials are now at an advanced stage.

The Jenner Institute is running trials at nine sites in Britain involving 10,000 volunteers, with others in Brazil and South Africa. Further trials are being run by its partners in India and the US.

The next critical stage in the process will be the 'unblinding' of trial results, which will see data from participants given the jab compared with the placebo group.

Until then, neither the participants nor the researchers leading trials themselves will know who has received the vaccine or the placebo – a process known as 'double blinding'. Professor Hill suggested that the unblinding is now imminent – but different countries' health regulators have different requirements before they license vaccines.

Researchers plan to seek emergency approval for vulnerable patients on the basis of interim results while conducting more trials to provide stronger evidence. 'The initial licence would be for emergency use, not full approval,' Professor Hill said.

"They will want to see more data on safety and maybe efficacy before they give a licence to vaccinate everybody. In this country, our priorities are pretty clear... we're going to vaccinate high-risk individuals before we vaccinate the young, the fit and healthy who are at lower risk. I think most countries will do that,"

"So what we're looking for this year is an 'emergency use' authorisation that will allow us to go and vaccinate those most at risk as a priority, then early next year everybody else.' Medics and other key workers would also be able to receive the vaccine under an interim licence," he added.

The professor said Britain's Medicines and Healthcare products Regulatory Agency has already been 'fantastic', adding, 'That's why we say this is one of the best countries in the world to do clinical trials – we have a well-informed, sensible regulator that makes decisions on the basis of a risk-based analysis, rather than a set of dogmatic rules.'

He said he would 'be very surprised if they don't move very fast' when interim results are submitted. Professor Hill suggested data based on as few as 20 cases of Covid could produce statistically significant evidence that the vaccine is effective – but this may not be enough to get the jab cleared in some countries.

Top News

Oxford University / Vaccine / ready / lead researcher / Christmas

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • TBS Sketch
    Framework agreement: What experts say about US 'security concerns' regarding Bangladesh
  • Representational image. Photo: Mohammad Minhaj Uddin/TBS
    Navy-run Dry Dock takeover boosts Ctg Port container handling, daily avg up 7%
  • BNP Secretary General Mirza Fakhrul Islam Alamgir speaks at a book unveiling event in Dhaka on 13 July 2025. Photo: Collected
    Fakhrul alleges conspiracy to eliminate Tarique from politics

MOST VIEWED

  • RAB Director General AKM Shahidur Rahman speaks at the press briefing on a fake bomb threat on Biman Bangladesh flight on Saturday, 12 July 2025. Photo: TBS
    Mother faked bomb threat on Biman flight to stop married son from flying with girlfriend: RAB
  • Bangladeshi garment workers make clothing in the sewing section of a factory in Gazipur, Bangladesh, April 9, 2025. Photo: REUTERS/Mohammad Ponir Hossain/File Photo
    Some Walmart garment orders from Bangladesh on hold due to US tariff threat
  • Infographic: TBS
    Dollar price plummets by Tk2.9 in a week as demand wanes
  • From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
    From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Dhaka, Washington yet to agree on 20% of US tariff conditions: BGMEA
  • Energy Adviser Fouzul Kabir Khan speaking about tariff negotiations with United States on 13 July 2025. Photo: TBS
    US wants a framework agreement with Bangladesh that includes their security concerns: Fouzul

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Somber Christmas in Bethlehem in the shadow of Gaza war

Features

Photo: Collected

Grooming gadgets: Where sleek tools meet effortless styles

8h | Brands
The 2020 Harrier's Porsche Cayenne coupe-like rear roofline, integrated LED lighting with the Modellista special bodykit all around, and a swanky front grille scream OEM Plus for the sophisticated enthusiast looking for a bigger family car that isn’t boring. PHOTO: Ahbaar Mohammad

2020 Toyota Harrier Hybrid: The Japanese Macan

1d | Wheels
The showroom was launched through a lavish event held there, and in attendance were DHS Motors’ Managing Director Nafees Khundker, CEO Imran Zaman Khan, and GMs Arman Rashid and Farhan Samad. PHOTO: Akif Hamid

GAC inaugurate flagship showroom in Dhaka

1d | Wheels
After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

2d | Panorama

More Videos from TBS

When the Threat Is Inside the White House

When the Threat Is Inside the White House

2h | Others
Shooting in Pallabi: What the police are saying

Shooting in Pallabi: What the police are saying

3h | TBS Stories
News of The Day, 13 JULY 2025

News of The Day, 13 JULY 2025

5h | TBS News of the day
Countries where Bangladeshis are not getting positive responses to their visa applications

Countries where Bangladeshis are not getting positive responses to their visa applications

4h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net